By Bonnie Eslinger
A California federal jury on Thursday found Eli Lilly breached the implied covenant of good faith and fair dealing in an agreement to co-develop Nektar Therapeutics' autoimmune-disease drug Rezpeg, awarding Nektar $90 million — a considerable sum that fell short of the $1 billion the clinical-stage biotech company had sought.
Read Full Article